209 |
Bleeke |
DNA Vaccines Encoding for GD2 Peptide Mimotopes Induce Anti-Neuroblastoma Immunity |
210 |
Huebener |
Mutated Ubiquitin Is Essential for Effective Therapeutic Vaccination with Tyrosine Hydroxylase DNA Minigenes Mediated by Antigen Specific CD8+ T Cells |
211 |
Khan |
Proteasome Inhibition Enhances the Antitumor/Antimetastatic Effects of Cytokine Therapy in Murine Neuroblastoma |
212 |
Yamashiro |
Resistance of MYCN-Amplified Neuroblastoma Xenografts to VEGF Blockade: Interaction of Notch and VEGF Pathways |
213 |
Keshelava |
Inhibition of Histone Deacetylase (HDAC1) by siRNA or Small Molecules Sensitizes Multi-Drug-Resistant Neuroblastoma (NB) Cell Lines to Commonly Used Chemotherapeutic Agents |
214 |
Ponzoni |
Combined Therapeutic Effects of Vinblastine and Rapamycin in Neuroblastoma |
215 |
Vitali |
Development of New Strategies for p53 Reactivation in Neuroblastoma |
216 |
Barbieri |
Inhibition of the p53-MDM2 Interaction Sensitizes Neuroblastoma to Apoptotic Cell Death |
217 |
Van Maerken |
Targeted Activation of the TP53 Pathway by the Small-Molecule MDM2 Antagonist Nutlin-3 as a New Therapy Concept for Neuroblastoma |
218 |
Pistoia |
Generation of Neuroblastoma-Specific Cytotoxic T Lymphocytes (CTL) Using Dendritic Cells Transfected with Tumor mRNA |
219 |
Tatsuta |
Immunotherapy for Neuroblastoma Using Dendritic Cell Stimulated by Sendai Virus Vector |
220 |
Chargui |
Cytolytic Effect of Vγ9δ2 T Cells on Autologous Neuroblastoma Cell Lines |
221 |
Jensen |
Humanized Antibodies Against the Neural Cell Adhesion Molecule (NCAM) Are Functionally Active Against Neuroblastoma in a SCID Mouse Model |
222 |
Croce |
Immunotherapy by IL-21-Engineered Neuro2a Cells in a Syngeneic Murine NB Model Involves CTL and Antibody Responses |
223 |
Hank |
The Functional Effects of Anti-Hu14.18 Antibody Activity Found in the Serum of Patients Following Infusion of Immunocytokine (IC) Hu14.18-IL2 for Treatment of Neuroblastoma |
224 |
Carlson |
Immunogenicity of Neuroblastoma in the Course of Differentiation |
225 |
Corrias |
Human NK Cell Infusions Prolong Survival of Metastatic Human Neuroblastoma-Bearing NOD/scid Mice |
226 |
Sheard |
Trail on Activated Natural Killer Cells Contributes to Their Cytotoxicity Against Neuroblastoma Cells Expressing TRAIL-R2 |
227 |
De Geer |
Cytotoxic T Lymphocytes Induce Caspase-Dependent and -Independent Cell Death in Neuroblastomas in a MHC-Non-Restricted Fashion |
228 |
Bleeke |
Optimization Strategies of Mimotopes for GD2 Directed Anti-Neuroblastoma Immunotherapy |
229 |
Jensen |
Bi-Specific Antibodies for Therapy of NCAM+ Neuroblastoma Induce Antigen Specific T Cell Expansion |
230 |
Orentas |
Discovery of New Immunologic Targets in Neuroblastoma by Vaccination in the Context of Regulatory T Cell Depletion: Immunodominance of the DEK Oncogene |
231 |
Tong |
Induction of Caspase 8 by 5-Azacytidine Renders NB Cells Sensitive to TRAIL |
232 |
Zhang |
The Effect of IFNγ on TRAIL-Induced Apoptosis in Neuroblastoma Cells |
233 |
Segerstrom |
The Anti-VEGF Antibody Bevacizumab Reduces the Growth Rate of High-Risk Neuroblastoma Xenografts |
234 |
Pastorino |
Combined Tumor- and Vascular-Targeting Enhances the Therapeutic Effects of Liposomal Chemotherapy Against Neuroblastoma |
235 |
Kaneko |
Relationship between Growth Inhibition of Neuroblastoma Xenograft and Expression of Hypoxia-Inducible Factor-1α/Vascular Endothelial Growth Factor by Prolonged Low-Dose CPT-11 Administration |
236 |
Varesio |
Transcriptional Response of Neuroblastoma to Hypoxia or to the Hypoxia Related Stimulus Picolinic Acid and Its Reversal by Topotecan |
237 |
Segerstrom |
Sensitivity of Endothelial Cell towards Commonly Used Chemotherapeutic Agents |
238 |
Johnsen |
A Novel Celecoxib Derivate, OSU03012, Induces Caspase-Dependent Cytotoxicity and Cell Cycle Arrest in Neuroblastoma |
239 |
Rasmuson |
Neuroblastoma Cells Express All Four Prostaglandin E2 (PGE2) Receptor Subtypes and Specific PGE2-Receptor Antagonists Inhibit Tumor Growth |
240 |
Keshelava |
Formalized Pre-Clinical Drug Testing To Facilitate Clinical Trial Development in the New Approaches to Neuroblastoma Therapy (NANT) Consortium |
241 |
Harned |
Sodium Thiosulfate (STS) Administered Six Hours after Cisplatin Does Not Compromise Anti-Neuroblastoma Activity |
242 |
Goldsmith |
Novel Pro-Death BH3 Peptidomimetics Re-Engage Apoptosis and Reverse Chemoresistance in Neuroblastoma |
243 |
Goldsmith |
Synthetic Small Molecule Bak-Domain Mimics Potently Induce Apoptosis in NB Cell Lines |
244 |
Raschella |
Activity of IGF1R Inhibitor NVP-AEW541 on Neuroblastoma Proliferation, Apoptosis and Invasion |
245 |
Kim |
In Multi-Drug Resistant Neuroblastoma Cell Lines, Sphingosine Kinase 1 mRNA Is Over-Expressed and Induced by Drugs Whose Resistance Is Modulated by Sphingosine Kinase Inhibitors |
246 |
Segerstrom |
Phosphorylated Akt and mTOR Is Abundantly Expressed in Neuroblastoma Tumours and Rapamycin and Its Analogue CCI-779 Show Promising Anti-Tumour Effects in Human Neuroblastoma |
247 |
Saulnier Sholler |
Isothiocynates and Derivatives Such as Sulforophane Induce Caspase Mediated Apoptosis in Neuroblastoma and Suppress AKT and ERK1/2 Signaling |
248 |
Armstrong |
Effects of BZ-423 on Cell Viability and N-myc Protein Stability in Neuroblastoma |
249 |
Armstrong |
Bortezomib as a Therapeutic Candidate for Neuroblastoma |
250 |
Valerie |
Toxicity of Velcade on Neuroblastoma Cell Lines |
251 |
Gleissman |
Omega-3 Docosahexaenoic Acid Is Toxic to Neuroblastoma In Vitro and In Vivo |
252 |
Hadjidaniel |
Antagonism of Etoposide Cytotoxicity for Neuroblastoma by Retinoic Acid Is Mediated by the Anti-Apoptotic bcl-2 Family Proteins |
253 |
Niizuma |
Bcl-2 Is a Key Regulator for the Retinoic Acid-Induced Apoptotisis of Neuroblastoma |
254 |
Armstrong |
Effect of R116010 on Retinoic Acid Metabolism and Efficacy in Neuroblastoma |
255 |
Ikegaki |
Retinoid-Resistance and Favorable Neuroblastoma Genes |
256 |
Redfern |
Over-Expression of RARγ Increases Death of SH-SY5Y Neuroblastoma Cells in Response to Retinoic Acid but Not to Fenretinide |
257 |
Liu |
Subcutaneous Tumor Exposure to Fenretinide in Neuroblastoma Murine Xenografts Is below Most Tissues and Potentially Limits Tumor Responses |
258 |
Imrie |
Bortezomib and Fenretinide-Induced Apoptosis: A Novel Approach to Adjuvent Therapy of Neuroblastoma? |
259 |
Lovat |
Fenretinide-Induced Apoptosis through Targeted Endoplasmic Reticulum Stress: Definition of Novel Targets for Neuroblastoma Therapy |
260 |
Lovat |
The NF-kB Pathway Mediates Fenretinide-Induced Apoptosis in SH-SY5Y Neuroblastoma Cells |
261 |
Armstrong |
p53-Independent Induction of NOXA in Response to Fenretinide [ndash] A Novel Therapeutic Strategy for Neuroblastoma? |
262 |
Kraveka |
Dihydroceramide Desaturase Enzyme as a Target for Neuroblastoma Therapy |
263 |
Ferrante |
Novel Cationic Ceramides as Chemotherapeutic Agents in Human Neuroblastoma Cells |
264 |
Wagner |
O6-Benzylguanine Pretreatment Sensitizes Neuroblastoma Cells to Temozolomide and Irinotecan Regardless of the Level of MGMT Expression |
265 |
Tamura |
Gefitinib Induces Apoptotic Cell Death in Neuroblastoma Cells |
266 |
Tabata |
Proteomic Analysis of Apoptosis Mechanism Induced by Xanthoangelol, a Major Chalcone Constituent of Angelica keiskei, in Neuroblastoma |
267 |
Gross |
Histone Deacetylase Inhibitors Strongly Sensitise Neuroblastoma Cells to TRAIL Induced Apoptosis by Caspases Dependent Increase of Pro- to Anti-Apoptotic Proteins Ratio |
268 |
Subramanian |
CREB-Binding Protein (CBP) Mediates Apoptotic Effects of Histone Deacetylase Inhibitors on Neuroblastoma (NB) Cells |
269 |
Wickstrom |
Activity of the Alkylating Dipeptide J1 in Neuroblastoma Cell Lines In Vitro and In Vivo |
270 |
Lokke |
The Antimicrobial Peptide LfcinB Is Cytotoxic to Neuroblastoma Cell Lines In Vitro and In Vivo |
271 |
Saulnier Sholler |
Combination Treatment of Nifurtimox with Buthionine Sulfoximine or Ascorbic Acid Enhances the Cytotoxicity to Neuroblastoma |
272 |
Bachmann |
Syringolin A, a New Plant Elicitor from the Phytopathogenic Bacterium Pseudomonas syringae pv. syringae, Induces Apoptosis in Human Neuroblastoma Cells |
273 |
Bagatell |
Effects of the Heat Shock Protein 90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin (17-DMAG) in Neuroblastoma Cells |
274 |
Jayanthan |
Studies on the Effectiveness and Biological Correlative Analysis of 17-DMAG on Neuroblastoma (NB) Cells |
275 |
Mairs |
Radiation Induced Biological Bystander Effect Elicited In Vitro by MIBG Labelled with Alpha-, Beta- and Auger Electron Emitting Radionuclides |
276 |
McCluskey |
[131I]Meta-Iodobenzylguanidine Targeted Radiotherapy: Utilising Tumour Specific and Radiation-Inducible Promoter Elements To Control NAT Gene Expression |
277 |
Yeung |
Arsenic Trioxide Can Induce G2/M Phase Cell Cycle Arrest in Selected Neuroblastoma Cell Lines |
278 |
Wang |
Neuronal Differentiation and TrkA Expression of Neuroblastoma Induced by the Combination Treatment of Interferon gamma and NGF |
279 |
Li |
Studies of Anti-Proliferation and Apoptosis after Combined Treatment of IFN-γ and Doxorubicin in Caspase-8 Silenced Neuroblastoma Cell Line |
280 |
Montaldo |
Antitumour Activity of Sodium Ascorbate Against Neuroblastoma Cell Lines In Vitro |
281 |
Bachmann |
Polyamine Depletion Induces p27Kip1, Downregulates MYCN, and Leads to Retinoblastoma Protein Rb-Mediated G1 Cell Cycle Arrest in MYCN-Amplified Human Neuroblastoma Cells |
282 |
Nara |
Silencing MYCN by RNA Interference Induces Growth Inhibition, Apoptotic Activity and Cell Differentiation in a Neuroblastoma Cell Line with MYCN Amplification |
283 |
Feng |
Targeted Delivery of MYCN siRNA Formulated in Folate Receptor-Targeted Lipid Vesicles into LA-N-5 Cells |
283a |
Garcia |
Comprehensive Profiling of the Cell Surface Proteome in Neuroblastoma Using Quantitative High Resolution Mass Spectrometry |
